In assessing the utility of APOMAB-immunoPET to detect immune-mediated tumour cell death after ICI therapy, we employed the MC38 tumour model in which sensitivity to PD-1 blockade has been shown [32] rather than the EL4 tumour model, which is not responsive to PD-1 blockade. This evidence concerns the gene PDCD1 and neoplasm.